News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
181,287 Results
Type
Article (17414)
Company Profile (129)
Press Release (163744)
Section
Business (58378)
Career Advice (935)
Deals (9388)
Drug Delivery (34)
Drug Development (23378)
Employer Resources (70)
FDA (2329)
Job Trends (4234)
News (92395)
Policy (5798)
Tag
Academia (483)
Alliances (16235)
Alzheimer's disease (395)
Antibody-drug conjugate (ADC) (56)
Approvals (2294)
Artificial intelligence (67)
Bankruptcy (76)
Best Places to Work (2892)
Biotechnology (119)
Breast cancer (65)
Cancer (551)
Career advice (754)
CAR-T (64)
Cell therapy (185)
Clinical research (18258)
Collaboration (262)
Compensation (51)
COVID-19 (733)
C-suite (76)
Data (500)
Diabetes (43)
Diagnostics (1050)
Drug discovery (44)
Earnings (15629)
Employer resources (68)
Events (30921)
Executive appointments (223)
FDA (2497)
Funding (222)
Gene therapy (118)
GLP-1 (234)
Government (608)
Healthcare (2416)
Infectious disease (775)
Inflammatory bowel disease (58)
Interviews (136)
IPO (4087)
Job creations (1472)
Job search strategy (701)
Layoffs (137)
Legal (1183)
Lung cancer (62)
Lymphoma (44)
Manufacturing (106)
Medical device (708)
Medtech (709)
Mergers & acquisitions (5401)
Metabolic disorders (161)
Neuroscience (536)
NextGen Class of 2024 (1470)
Non-profit (488)
Northern California (621)
Obesity (88)
Opinion (167)
Patents (42)
People (21943)
Phase I (7092)
Phase II (8712)
Phase III (4913)
Pipeline (230)
Postmarket research (306)
Preclinical (2895)
Press Release (61)
Radiopharmaceuticals (79)
Rare diseases (116)
Real estate (2434)
Regulatory (4380)
Research institute (525)
Resumes & cover letters (152)
Series A (49)
Southern California (588)
Startups (1780)
United States (5244)
Vaccines (186)
Weight loss (69)
Date
Last 7 days (261)
Last 30 days (916)
Last 365 days (12685)
2024 (12634)
2023 (13291)
2022 (16091)
2021 (16975)
2020 (13240)
2019 (9665)
2018 (7695)
2017 (9016)
2016 (8159)
2015 (9466)
2014 (9749)
2013 (9463)
2012 (6097)
2011 (6478)
2010 (5867)
Location
Africa (327)
Asia (13359)
Australia (2651)
California (1444)
Canada (528)
China (126)
Connecticut (59)
Europe (29820)
Florida (146)
Illinois (106)
Indiana (76)
Maryland (220)
Massachusetts (1142)
Michigan (62)
Minnesota (96)
New Jersey (408)
New York (369)
North Carolina (272)
Northern California (621)
Ohio (41)
Pennsylvania (312)
South America (405)
Southern California (588)
Texas (157)
Washington State (260)
181,287 Results for "legend biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
CAR-T
J&J, Legend Shrug Off Carvykti’s Challengers With New Phase III Data
With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off competition from emerging CAR T therapies such as Gilead and Arcellx’s anito-cel.
December 11, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 20, 2024
·
1 min read
Press Releases
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
November 5, 2024
·
4 min read
CAR-T
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti
Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.
December 10, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
Legend Biotech Corporation today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m. ET.
May 29, 2024
·
1 min read
Business
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
Legend Biotech Corporation, a global leader in cell therapy, reported its first quarter 2024 unaudited financial results and key corporate highlights.
May 13, 2024
·
11 min read
Drug Development
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today results for the first time from the Phase 2 CARTITUDE-2 Cohort D study in multiple myeloma patients.
June 3, 2024
·
31 min read
BioCapital
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
MaxCyte, Inc. announced it has entered into a strategic platform license agreement with Legend Biotech, a global leader in cell therapy.
May 22, 2024
·
7 min read
Pharm Country
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.
April 11, 2024
·
1 min read
Drug Development
J&J, Legend’s Phase III Win Cements Carvykti as Earlier-Line Multiple Myeloma Treatment
Johnson & Johnson and Legend Biotech’s Carvykti cell therapy significantly improved survival in patients with multiple myeloma when used in the second-line setting, the companies announced on Tuesday.
July 3, 2024
·
2 min read
·
Tristan Manalac
1 of 18,129
Next
